Pharma Pulse: Retatrutide's Black Market Problem, BMS's Houston Bet, FDA's DSCSA Assessment

In this week's Pharma Pulse, Eli Lilly sues companies over black-market retatrutide sales, Bristol Myers Squibb commits $2.3 billion to a new Houston manufacturing campus, and FDA opens an assessment of small dispensers' DSCSA tracing capabilities.